Royalty Pharma plc Stock Issued During Period, Value, Employee Benefit Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Royalty Pharma plc stock issued during period, value, employee benefit plan for the quarter ending 2026-06-30 was $48.47M, a 25.14% decline year-over-year.
- Royalty Pharma plc stock issued during period, value, employee benefit plan for the quarter ending 2026-03-31 was $47.48M.
- Royalty Pharma plc stock issued during period, value, employee benefit plan for the quarter ending 2025-12-31 was $35.47M.
- Royalty Pharma plc stock issued during period, value, employee benefit plan for the quarter ending 2025-09-30 was $35.55M.
- Royalty Pharma plc stock issued during period, value, employee benefit plan for fiscal 2025 was $136.28M.
| Period end | Stock Issued During Period, Value, Employee Benefit Plan 3 month | Stock Issued During Period, Value, Employee Benefit Plan 12 month |
|---|---|---|
| 2026-06-30 | $48.47M 10-Q · filed 2026-08-05 | $166.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $47.48M 10-Q · filed 2026-05-06 | $183.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $35.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $136.28M 10-K · filed 2026-02-11 |
| 2025-09-30 | $35.55M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $64.75M 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |